Helix BioPharma (TSE:HBP) Shares Pass Below 200-Day Moving Average – Time to Sell?

Helix BioPharma Corp. (TSE:HBP) shares passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of C$1.87 and traded as low as C$1.35. Helix BioPharma shares last traded at C$1.40, with a volume of 798 shares traded.

Helix BioPharma Stock Up 2.2%

The company’s 50 day moving average price is C$1.61 and its two-hundred day moving average price is C$1.87. The company has a current ratio of 0.45, a quick ratio of 1.03 and a debt-to-equity ratio of 2.44. The firm has a market cap of C$106.93 million, a PE ratio of -35.00 and a beta of 0.42.

Helix BioPharma (TSE:HBP) last posted its quarterly earnings data on Friday, June 12th. The biopharmaceutical company reported C($0.01) EPS for the quarter. On average, equities research analysts expect that Helix BioPharma Corp. will post -0.11 EPS for the current fiscal year.

About Helix BioPharma

Helix BioPharma is an oncology company that innovates from strength to bring near-term solutions for today’s hardest-to-treat cancers. The Company’s pipeline is led by Tumor Defense Breaker¿ L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy and augment the effectiveness of today’s front-running anti-cancer treatments. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its CEACAM6-targeting foundation with Helix’s next-generation bi-specific antibody-drug conjugates (ADCs), currently in discovery.